New Hope for Advanced NET Patients | Glasgow News

Big news for Scottish patients: the SMC has approved cabozantinib (Cabometyx) for advanced neuroendocrine tumours, offering renewed hope and a much-needed treatment option when other choices are exhausted. This oral drug helps slow cancer progression, improves quality of life, and reduces hospital visits — a major win for patients and families battling these often-delayed, debilitating cancers. Ipsen celebrates the milestone as a step forward in rare cancer care. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/39757d58f4c661fd